65,437 trials
Spondyloarthritis
Primary: Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response in Biological Disease-modifying Antirheumatic Drug…
Carcinoid Tumor · Metastatic Carcinoid Tumor · Neuroendocrine Neoplasm
Primary: PFS — 11 months
Asthma
Primary: Patients Who Achieve 100% Reduction in Daily OCS Dose — 376 Participants
Clinical Decision Support · Buprenorphine · Opioid-use Disorder
Primary: Count of Initiating BUP in the ED With Referral for Ongoing MOUD With User-centered CDS Compared With Usual Care — 347; 271 Participants — p=0.58
Oxygen Deficiency
Primary: Accuracy of O3 Sensor by ARMS Calculation of Percent rSO2 — 4.78 percentage of regional oxygen saturation
Abdominal Neoplasms
Primary: Capability of Performing EUS-FNTA Through the Duodenum by Placing the Target Lesion in the Proper Position With Insertion of the Needle Into the Lesion — 228 Participants
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy (BAT) — 9; 5; 4; 2 Participants
Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Primary: Relapse-free Survival (RFS) Per Independent Review Committee (IRC) Adjudication — 24.02; 15.84 Months — p=0.163
Generalized Myasthenia Gravis
Primary: Main Portion: Change From Baseline to Week 12 in Quantitative Myasthenia Gravis (QMG) Score — -5.5; -6.0; -3.2 score on a scale — p==0.0941
Cocaine Use Disorder
Primary: Feasibility as Assessed by Number of Participants Who Completed Treatment — 3 Participants
Hemophilia B
Primary: Number of Participants With Adverse Events — 5; 5 participants
Anemia · Non-Dialysis-Dependent Chronic Kidney Disease
Primary: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) — 1.43; 1.38 g/dL
Coronary Artery Disease · Peripheral Arterial Disease · Atrial Fibrillation
Primary: Platelet-Mediated Global Thrombogenicity — 66; 59; 69; 71 percentage of aggregation — p=0.275
Anemia · Non-Dialysis-Dependent Chronic Kidney Disease
Primary: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) — 0.41; 0.42 Grams per deciliter (g/dL)
Induction of Labor
Primary: Time to Delivery — 19.2; 24.3 hours — p=0.04